Geno2pheno[HCV] - A web-based interpretation system to support hepatitis c treatment decisions in the era of direct-acting antiviral agents

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Kalaghatgi, Prabhav ^a   Maria Sikorski, Anna ^b,c   Knops, Elena ^b   Rupp, Daniel ^c   Sierra, Saleta ^b   Heger, Eva ^b   Neumann Fraune, Maria ^b   Beggel, Bastian ^a   Walker, Andreas ^d   Timm, Jörg ^d   Walter, Hauke ^e   Obermeier, Martin ^e   Kaiser, Rolf ^b   Bartenschlager, Ralf ^c   Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e Medizinisches Infektiologiezentrum Berlin Mib   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ALGORITHM; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELL CULTURE TECHNIQUE; COMPUTER INTERFACE; COMPUTER PREDICTION; COMPUTER PROGRAM; DECISION MAKING; DRUG SENSITIVITY; GENE SEQUENCE; GENO2PHENO; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS C; HUMAN; LIMIT OF DETECTION; PERSONALIZED MEDICINE; PHENOTYPE; SEQUENCE ANALYSIS; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; IC50; INTERNET; MUTATION; SOFTWARE; VIRUS GENOME;

ALGORITHMS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENETIC ASSOCIATION STUDIES; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERNET; MUTATION; OLIGOPEPTIDES; PHENOTYPE; PROLINE; SIMEPREVIR; SOFTWARE;

EID: 84969766597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155869     Document Type: Article

References (82)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333-1342. doi: 10.1002/hep.26141 PMID: 23172780
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365: 1118-1127. doi: 10.1056/NEJMra1001683 PMID: 21992124
3. Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol. 2014; 20: 2876-2887. doi: 10.3748/wjg.v20.i11.2876 PMID: 24659879
4. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013; 11: 482-496. doi: 10.1038/nrmicro3046 PMID: 23748342
5. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013; 110: 3991-3996. doi: 10.1073/pnas.1203110110 PMID: 23431163
6. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998; 282: 103-107. PMID: 9756471
7. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991; 88: 3392-3396. PMID: 1849654
8. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology. 2007; 132: 1757-1766. PMID: 17484873
9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42: 962-973. PMID: 16149085
10. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59: 318-327. doi: 10.1002/hep.26744 PMID: 24115039
11. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014; 34 Suppl 1: 69-78. doi: 10.1111/liv.12423 PMID: 24373081
12. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med. 2015; 7: 51-70. doi: 10.2147/HMER.S55864 PMID: 26586968
13. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62: S87-99. doi: 10.1016/j.jhep.2015.02.006 PMID: 25920094
14. EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63: 199-236. doi: 10.1016/j.jhep.2015.03.025 PMID: 25911336
15. AASLD-IDSA (2015) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
16. De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, et al. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infectious Diseases. 2015; 2: 1-9.
17. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother. 2009; 53: 2129-2132. doi: 10.1128/AAC.01598-08 PMID: 19273674
18. Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One. 2012; 7: e39652. doi: 10.1371/journal.pone.0039652 PMID: 22792183
19. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011; 53: 1742-1751. doi: 10.1002/hep.24262 PMID: 21374691
20. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013; 58: 902-911. doi: 10.1002/hep.26388 PMID: 23504694
21. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013; 58: 646-654. doi: 10.1016/j.jhep.2012.11.012 PMID: 23178977
22. Itakura J, Kurosaki M, Takada H, Nakakuki N, Matsuda S, Gondou K, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015; 45: E115-121. doi: 10.1111/hepr.12474 PMID: 25564756
23. Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Roberts S, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013; 57: 2054-2065. doi: 10.1128/AAC.02494-12 PMID: 23403428
24. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013; 57: 221-229. doi: 10.1093/cid/cit226 PMID: 23575197
25. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013; 444: 329-336. doi: 10.1016/j.virol.2013.06.029 PMID: 23876458
26. Neumann-Fraune M, Beggel B, Kaiser R, Obermeier M. Hepatitis B virus drug resistance tools: one sequence, two predictions. Intervirology. 2014; 57: 232-236. doi: 10.1159/000361076 PMID: 25034493
27. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 2003; 31: 3850-3855. PMID: 12824435
28. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007; 25: 1407-1410. PMID: 18066037
29. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat. 2011; 18: 608-618. doi: 10.1111/j.1365-2893.2010.01342.x PMID: 20565573
30. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004; 279: 17508-17514. PMID: 14766754
31. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005; 280: 36784-36791. PMID: 16087668
32. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132: 1767-1777. PMID: 17484874
33. He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother. 2008; 52: 1101-1110. PMID: 18086851
34. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 2008; 77: 177-185. doi: 10.1016/j.antiviral.2007.11.010 PMID: 18201776
35. Zhou Y, Bartels DJ, Hanzelka BL, Muh U, Wei Y, Chu HM, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2008; 52: 110-120. PMID: 17938182
36. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009; 50: 1709-1718. doi: 10.1002/hep.23192 PMID: 19787809
37. Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010; 54: 5288-5297. doi: 10.1128/AAC.00777-10 PMID: 20855726
38. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010; 54: 1878-1887. doi: 10.1128/AAC.01452-09 PMID: 20176898
39. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One. 2012; 7: e34372. doi: 10.1371/journal.pone.0034372 PMID: 22511937
40. Lagacé L, White PW, Bousquet C, Dansereau N, Do F, Llinas-Brunet M, et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother. 2012; 56: 569-572. doi: 10.1128/AAC.05166-11 PMID: 22024816
41. Lam JT, Jacob S. Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm. 2012; 69: 2135-2139. doi: 10.2146/ajhp110500 PMID: 23230035
42. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012; 56: 5387-5396. doi: 10.1128/AAC.01186-12 PMID: 22869577
43. Susser S, Schelhorn S, Lange C, Welsch C, Vermehren J, Perner D, et al. Ultratiefe Pyrosequenz-Analyse (UDPS) von neu beschriebenen seltenen Resistenzvarianten der Hepatitis C Virus NS3 Protease bei Patienten, die mit Telaprevir oder Boceprevir behandelt wurden. Z Gastroenterol. 2012; 50.
44. Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother. 2012; 56: 1350-1358. doi: 10.1128/AAC.05977-11 PMID: 22214777
45. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med. 2012; 20: 139-145. PMID: 23154254
46. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013; 8: 1930-1940. doi: 10.1002/cmdc.201300343 PMID: 24127258
47. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013; 57: 13-18. doi: 10.1016/j.jcv.2012.12.020 PMID: 23384816
48. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-1887. doi: 10.1056/NEJMoa1214853 PMID: 23607594
49. Lawitz E, Poordad F, Membreno FE, Hyland H, Ding X, Hebner C, et al. Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in ≥95% Sustained Virologic Response In Patients with HCV Genotype 1, Including Patients with Cirrhosis: the LONESTAR trial; 2013 November 1-5, 2013; Washington, DC, USA. pp. Abstract 215.
50. Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013; 58: 445-451. doi: 10.1016/j.jhep.2012.10.028 PMID: 23142061
51. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother. 2013; 57: 611-613. doi: 10.1128/AAC.01874-12 PMID: 23089758
52. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483-1493. doi: 10.1056/NEJMoa1316366 PMID: 24725238
53. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013; 57: 6333-6340. doi: 10.1128/AAC.02193-12 PMID: 23877691
54. Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014; 59: 1657-1665. doi: 10.1093/cid/ciu696 PMID: 25266289
55. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014; 60: 490-499. doi: 10.1016/j.jhep.2013.10.019 PMID: 24444658
56. McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther. 2014; 19: 479-490. doi: 10.3851/IMP2729 PMID: 24448487
57. Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, et al. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother. 2014; 58: 2105-2112. doi: 10.1128/AAC.02068-13 PMID: 24468783
58. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014; 209: 668-675. doi: 10.1093/infdis/jit562 PMID: 24154738
59. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014; 59: 1666-1674. doi: 10.1093/cid/ciu697 PMID: 25266287
60. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1604-1614. doi: 10.1056/NEJMoa1401561 PMID: 24720679
61. Chayama K, Hayes CN. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses. 2015; 7: 5328-5342. doi: 10.3390/v7102876 PMID: 26473914
62. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015; 61: 56-65. doi: 10.1002/hep.27375 PMID: 25123381
63. Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, et al. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrob Agents Chemother. 2015; 59: 7426-7436. doi: 10.1128/AAC.01953-15 PMID: 26392503
64. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015; 59: 1505-1511. doi: 10.1128/AAC.04619-14 PMID: 25534735
65. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015; 59: 979-987. doi: 10.1128/AAC.04226-14 PMID: 25451055
66. McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype1b Without Baseline NS5A Polymorphisms. Adv Ther. 2015; 32: 637-649. doi: 10.1007/s12325-015-0221-5 PMID: 26155891
67. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015; 313: 1232-1239. doi: 10.1001/jama.2015.1373 PMID: 25706232
68. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015; 59: 988-997. doi: 10.1128/AAC.04227-14 PMID: 25451053
69. Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir. Antimicrob Agents Chemother. 2015; 59: 6807-6815. doi: 10.1128/AAC.01229-15 PMID: 26282418
70. EMA DAKLINZA: SUMMARY OF PRODUCT CHARACTERISTICS. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003768/WC500172848.pdf, Latest accessed: Dez 8, 2015
71. EMA EXVIERA: SUMMARY OF PRODUCT CHARACTERISTICS. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003837/WC500182233.pdf, Latest accessed: Dez 8, 2015
72. EMA VIEKIRAX: SUMMARY OF PRODUCT CHARACTERISTICS. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003839/WC500183997.pdf, Latest accessed: Dez 8, 2015
73. EMA HARVONI: SUMMARY OF PRODUCT CHARACTERISTICS. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003850/WC500177995.pdf, Latest accessed: Dez 8, 2015
74. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos HCV Sequence Database. Bioinformatics. 2005; 21: 379-384. PMID: 15377502
75. Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 2009; 81: 166-173. doi: 10.1016/j.antiviral.2008.11.002 PMID: 19063924
76. Sierra S, Kaiser R, Lubke N, Thielen A, Schuelter E, Heger E, et al. Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp. 2011.
77. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol. 2001; 75: 12047-12057. PMID: 11711595
78. Schmitt M, Scrima N, Radujkovic D, Caillet-Saguy C, Simister PC, Friebe P, et al. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol. 2011; 85: 2565-2581. doi: 10.1128/JVI.02177-10 PMID: 21209117
79. Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015; 62: 1008-1014. doi: 10.1016/j.jhep.2014.11.032 PMID: 25445400
80. Sulkowski M, Ghalib R, Rodriguez-Torres M, Younoss iZ, Corregidor A, Fevery B, et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0-2: Cosmos study subgroup analysis. J Hepatol. 2014; 60: S4.
81. Lawitz E, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, DeJesus E, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (Cosmos study): primary endpoint (SVR12) results in patients with metavir F3-4 (Cohort 2). J Hepatol. 2014; 60: S524.
82. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013; 58: 1918-1929. doi: 10.1002/hep.26641 PMID: 23907700